Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: L04AA06

CellCept(mycophenolate mofetil)

Graft Rejection

Marketing Authorisation Holder: Roche Registration GmbH

EMA Authorisation: 14/02/1996

INN: mycophenolate mofetil

Indication

CellCept is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in adult and paediatric (1 to 18 years of age) patients receiving allogeneic renal, cardiac or hepatic transplants.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about CellCept — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.